- Drug developer surged 200% on December trial data, deal hopes
- Stock faltered this week on disappointment over lack of a bid
Traders expecting to make good on Cytokinetics Inc. takeover bets found themselves on a white-knuckle ride as prospects for a deal whipsawed shares.
Cytokinetics was already a takeover favorite when a batch of positive trial data hit in December. In the weeks that followed, shares soared nearly 200% amid multiple reports of buyer interest. But when a key meeting — the JPMorgan Healthcare Conference, a mecca for deals — opened with a flurry of transactions but no bid for Cytokinetics, shares started to fade only to be reignited by new rumors before hopes were dashed again.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.